OSE Immunotherapeutics To Present Step-1 Results of Phase 3 Clinical Trial of Tedopi® ‘Atalante 1’ in Non-Small Cell Lung Cancer at the European Society for Medical Oncology (ESMO) Virtual Congress 2020

NEXT STORY
Basilea announces completion of its transaction involving a partial repurchase of its existing bond and the issuance of a new bond
PREV STORY
Knee Replacement Market to Reach USD 12.48 Billion by 2027; Rising Awareness about Early Diagnosis to Boost Market, states Fortune Business Insights™
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

ASLAN Pharmaceuticals Announces Strategic Prioritisation of Clinical Development Programs and Corporate Restructuring

SINGAPORE, Jan. 29, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology-focused ...

author_avatar
NASDAQ Market News

G1 Therapeutics Announces Closing of Offering of Common Stock

RESEARCH TRIANGLE PARK, N.C., March 12, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq:GTHX), ...

author_avatar
NASDAQ Market News

Anavex Life Sciences Presents New Three-Year, Longitudinal Clinical Efficacy Data for ANAVEX®2-73 in Alzheimer’s Disease at the 2018 Clinical Trials on Alzheimer’s Disease (CTAD) Meeting

Late-Breaking Data Demonstrate Significant Association Between Higher ANAVEX®2-73 Concentration and Maintained Activities of Daily ...

author_avatar
NASDAQ Market News